1. Potassium-chelating drug sodium polystyrene sulfonate enhances lysosomal function and suppresses proteotoxicity
- Author
-
Cyrene Arputhasamy, Anna C. Foulger, Mark Lucanic, Anand Rane, Minna Schmidt, Theo Garrett, Michael Broussalian, Elena Battistoni, Rachel B. Brem, Gordon J. Lithgow, Manish Chamoli, and Julie K. Andersen
- Subjects
Aging ,Short Communication ,Geriatrics and Gerontology - Abstract
Lysosomes are crucial for degradation and recycling of damaged proteins and cellular components. Therapeutic strategies enhancing lysosomal function are a promising approach for aging and age-related neurodegenerative diseases. Here, we show that an FDA approved drug sodium polystyrene sulfonate (SPS), used to reduce high blood potassium in humans, enhances lysosomal function both in C. elegans and in human neuronal cells. Enhanced lysosomal function following SPS treatment is accompanied by the suppression of proteotoxicity caused by expression of the neurotoxic peptides Aβ and TAU. Additionally, treatment with SPS imparts health benefits as it significantly increases lifespan in C. elegans. Overall our work supports the potential use of SPS as a prospective geroprotective intervention. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11357-022-00647-8.
- Published
- 2022